Xencor’s IL2-Fc Cytokine, XmAb®564, is Well-tolerated and Selectively Expands Regulatory T Cells in Phase 1a Clinical Study

MONROVIA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced topline clinical data from its Phase 1a single-dose, healthy volunteer study of XmAb®564, in development for patients with autoimmune diseases. XmAb564 is a wholly owned, monovalent...

Click to view original post